| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.84(B) |
| Last
Volume: |
2,691,736 |
Avg
Vol: |
3,233,465 |
| 52
Week Range: |
$525.19 - $960.02 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 412 |
| Guru Rank Value : 5.2 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
477,582 |
1,998,159 |
3,084,579 |
6,508,552 |
| Total Sell Value |
$445,314,912 |
$1,729,973,767 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
3 |
3 |
6 |
| Total Sell Transactions |
10 |
28 |
43 |
97 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jonsson Patrik |
SVP & President Lilly USA |
• – – |
2021-02-08 |
4 |
A |
$205.77 |
$1,151,283 |
D/D |
5,595 |
30,674 |
|
- |
|
| Ashkenazi Anat |
SVP & CFO |
• – – |
2021-02-08 |
4 |
A |
$205.77 |
$1,641,016 |
D/D |
7,975 |
25,675 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$1,757,762 |
D/D |
(8,452) |
52,250 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,266 |
60,702 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$1,557,695 |
D/D |
(7,490) |
27,910 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,754 |
35,400 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$499,752 |
D/D |
(2,403) |
25,022 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,445 |
27,425 |
|
- |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$593,546 |
D/D |
(2,854) |
7,738 |
|
- |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,282 |
10,592 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$317,986 |
D/D |
(1,529) |
19,424 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,435 |
20,953 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$1,130,941 |
D/D |
(5,438) |
51,481 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,146 |
56,919 |
|
- |
|
| Shah Aarti S. |
SVP & CIDO |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$578,157 |
D/D |
(2,780) |
20,589 |
|
- |
|
| Shah Aarti S. |
SVP & CIDO |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,282 |
23,369 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2021-02-01 |
4 |
D |
$207.97 |
$1,402,966 |
D/D |
(6,746) |
108,543 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,078 |
115,289 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2021-02-01 |
4 |
D |
$207.97 |
$7,016,492 |
D/D |
(33,738) |
309,901 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,387 |
343,639 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-01-19 |
4 |
A |
$198.48 |
$1,985 |
D/D |
10 |
59,732 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-01-19 |
4 |
A |
$198.48 |
$10,916 |
D/D |
55 |
49,144 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-01-15 |
4 |
S |
$189.30 |
$41,022,862 |
D/D |
(215,000) |
110,487,343 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-01-13 |
4 |
S |
$185.40 |
$39,053,064 |
D/D |
(210,000) |
110,702,343 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-01-11 |
4 |
S |
$184.87 |
$40,807,754 |
D/D |
(220,000) |
110,912,343 |
|
- |
|
1436 Records found
|
|
Page 21 of 58 |
|
|
15.24 (1.65%) 
